You appear to be far too impatient. Let's remember the independent data monitoring committee has not even done an interim analysis for our Phase II trial. Nobody even knows we exist. However, once the DMC gives us a clean bill of health on safety and toxicity for interim results and instructs us to proceed with this revolutionary trial we will most likely get a significant bump.
As another poster mentioned, the Feuerstein-Ratain rule assesses a company's market capitalization 3 months before Phase III results are released to predict success or failure. That threshold is $300 million for the first tier. No company has had successful Phase III results if their cap rate is below $300 million 3 months prior to release results.
I have not seen market cap threshold metrics regarding FDA success or failure for companies prior to Phase II interim results. Maybe you could point to established market rules or theories. I doubt it. Maybe you need to be a bit more patient. All the best and GL.